Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET.

GlobeNewsWire • Oct 27, 2026

Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation

– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation – – Nominations open November 1, 2026, and close December 31, 2026; winner to be recognized in mid-2027 – NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the return of the Arvinas Early Career Researcher Award, which recognizes the research of an emerging researcher or research team bringing innovation, new approaches and creative thinking to the field of targeted protein degradation (TPD).

GlobeNewsWire • Oct 27, 2026

Reasons Why Investors Should Consider Betting on Arvinas Stock

ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.

Zacks Investment Research • Oct 13, 2026

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease

– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –

GlobeNewsWire • Oct 7, 2026

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®

NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson's Disease and Movement Disorders® (MDS), taking place October 4-8, 2026, in Seoul, Korea.

GlobeNewsWire • Oct 1, 2026

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.

GlobeNewsWire • Sep 29, 2026

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

GlobeNewsWire • Sep 28, 2026

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:

GlobeNewsWire • Sep 3, 2026

Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish

Arvinas receives a Buy rating upgrade, underpinned by Veppanu's FDA approval and a robust PROTAC platform. Despite Veppanu's approval for ESR1-mutated breast cancer, ARVN's share price remains near cash value, reflecting market skepticism about future revenues. ARVN's pipeline includes five early-stage programs and a Novartis-partnered asset, but high R&D costs and uncertain milestones temper near-term upside.

Seeking Alpha • Aug 28, 2026